A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease.

Trial Profile

A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart Disease.

Completed
Phase of Trial: Phase III

Latest Information Update: 08 May 2014

At a glance

  • Drugs Ezetimibe (Primary) ; Rosuvastatin
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ACTE
  • Sponsors Merck & Co
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 17 May 2011 Results published in the American Journal of Cardiology.
    • 19 May 2010 Actual patient number (440) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top